Major indications for GRIFULVIN V® (griseofulvin tablets) microsize are:

• Tinea capitis (ringworm of the scalp)

• Tinea corporis (ringworm of the body)

• Tinea pedis (athlete’s foot)

• Tinea unguium (onychomycosis; ringworm of the nails)

• Tinea cruris (ringworm of the thigh)

• Tinea barbae (barber’s itch)

GRIFULVIN V® (griseofulvin tablets) microsize inhibits the growth of those genera of fungi that commonly cause ringworm infections of the hair, skin, and nails, such as:

• Trichophyton rubrum

• Trichophyton tonsurans

• Trichophyton mentagrophytes

• Trichophyton interdigitalis

• Trichophyton verrucosum

• Trichophyton sulphureum

• Trichophyton schoenleini

• Microsporum audouini

• Microsporum canis

• Microsporum gypseum

• Epidermophyton floccosum

• Trichophyton megnini

• Trichophyton gallinae

• Trichophyton crateriform

Note: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical antifungal agents alone.

It is not effective in^[1]:

• Bacterial infections

• Candidiasis (Moniliasis)

• Histoplasmosis

• Actinomycosis

• Sporotrichosis

• Chromoblastomycosis

• Coccidioidomycosis

• North American Blastomycosis

• Cryptococcosis (Torulosis)

• Tinea versicolor

• Nocardiosis

Adapted from the FDA Package Insert.